Table 3.
Intravitreal protein concentrations in nonstatin- and statin-treated iERM patients
| Nonstatin (n=14) | Statin (n=12) | P-value | |
|---|---|---|---|
| Total protein | 3.3±2.3 | 4.1±1.3 | 0.095 |
| ANGPT-1 | 27.8±39.1 | 12.3±6.1 | 0.145 |
| ANGPT-2 | 82.9±108.5 | 31.8±22.0 | 0.176 |
| EPO | 82.9±119.5 | 10.8±4.9 | 0.003 |
| MMP-2 | 1,710.0±1,185.7 | 854.1±496.8 | 0.072 |
| MMP-9 | 36.7±47.7 | 43.8±77.5 | 1.000 |
| TGF-β1 | 15.8±16.3 | 2.3±4.7 | 0.035 |
| VEGF | 236.6±491.6 | 5.5±9.9 | 0.006 |
Notes: The intravitreal concentrations (ANGPT-1 and -2, VEGF, TGF-β1 [pg/mL]; EPO [mIU/mL]; or MMP-2 and -9 [AU/mL]) in eyes with iERM are given in relation to total protein concentration (mg/mL) in the vitreous sample. Data presented as mean ± SEM. For two-group comparisons, a nonparametric Mann–Whitney U-test was used. P≤0.05 shows a statistically significant result between the groups.
Abbreviations: ANGPT, angiopoietin; EPO, erythropoietin; iERM, idiopathic epiretinal membrane; MMP, matrix metalloproteinase; SEM, standard error of mean; TGF-β1, transforming growth factor-β1; VEGF, vascular endothelial growth factor.